Aureus Pharma has extended its knowledge database agreement with sanofi-aventis research & development for an additional three-year term. Under the agreement, Aureus will provide new AurSCOPE knowledge databases
BioCryst Pharmaceuticals has received an initial order for 10,000 courses of intravenous (i.v.) peramivir (600 mg once-daily for five days) with a value of $22.5m under a newly
NovaDel Pharma (NovaDel) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for claims under US Patent Application No 10/671,715, entitled; Buccal, Polar
Ligand Pharmaceuticals has extended its research collaboration with Pfizer for JAK3 by one year. The research and license agreement entered with Wyeth provided for an initial three year
It covers a method of treating insomnia by administering zolpidem to humans utilising NovaMist oral spray. NovaDel’s Zolpimist (zolpidem tartrate) 5 mg and 10 mg oral spray product
DSM Pharmaceutical has entered into a manufacturing alliance with Galenix where DSM will be the preferred commercial scale manufacturing partner for Galenix commercial products on a global basis.
The study was aimed at comparing the bioavailability and pharmacokinetics of cyclosporine after intravenous administration of NeuroSTAT, a Cremophor EL-free lipid emulsion, and Sandimmune Injection in healthy volunteers.
Pennsaid Topical Solution is a non-steroidal anti-inflammatory drug used for the treatment of the signs and symptoms of osteoarthritis of the knee. Dan Chicoine, chairman of Nuvo Research,
Theravance and Astellas Pharma have commercially launched Vibativ (telavancin) in the US. FDA approved Vibativ for the treatment of adult patients with complicated skin and skin structure infections
FDA has launched Safe Use Initiative, a program aimed at reducing the likelihood of preventable harm from medication use. Margaret Hamburg, commissioner of FDA and Janet Woodcock, director
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.